Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Yokogawa to supply integrated SCADA for Melbourne Water

A process of evolution: creating an adaptive future for the industrial workforce

Australian industry contracts in F‍-‍35 program worth over $5 billion

Newmont deploys 'world‍ first' 5G teleremote dozer fleet at Cadia mine

Mitsubishi and Rio Tinto to participate in hydrogen‍-‍based ironmaking

Resource-saving greenfield brewery being built in Germany

In-house ginger processing for beverage maker

Tailor-made solutions for sliced meat on show at IFFA

Food of the future: Anuga presents food trends for 2025

Tree sap: a plant-based gelatine alternative?

New membranes could help eliminate brine waste at desalination plants

Emissions as data: the challenge of reporting on an invisible metric

Fluoride boosts water-processed perovskite solar cells

New filter tech targets PFAS in water

Reaching net zero in the manufacturing sector

Lonza bone marrow and cord blood mononuclear cells

Cytek Tonbo Reagents

Selleck Chemicals FDA-approved Anticancer Drug Library

Cytek Tonbo Mouse TBNK/Myeloid/Treg Kit

Content from other channels on our network